Qiagen launches CRISPR products to aid in edited genetic material analysis

By The Science Advisory Board staff writers

June 23, 2021 -- Qiagen has rolled out its QIAprep & CRISPR Kit and CRISPR Q-Primer Solutions. The products are intended to support researchers in analyzing edited genetic material to identify how their interventions have changed the function of the DNA sequence in question.

The products provide scientists an all-in-one process for characterizing knockouts generated from guide RNA (gRNA) and knockins from small insertions during gene editing. The kit and Q-Primer solutions combine liquid-based sample preparation with polymerase chain reaction (PCR) detection and the Sanger method of DNA sequencing. Qiagen's new products can be used to analyze cells edited with methods such as CRISPR with adherent and suspension cell cultures and can be used in experiments with the proteins Cas9 and Cas12a or single-cell inputs.

Positive PCR controls for humans, mice, and rats are included to determine the effectiveness of the gene editing conditions.

The kit and solutions will also decrease the time to result in experiments, with cell cultivation requirements reduced by seven days compared with existing methods, Qiagen said.

Qiagen posts strong sales, earnings growth in Q1
Strong growth in both COVID-19 and non-COVID-19 product groups propelled Qiagen to a 48% increase in net sales at constant exchange rates in its first...
Qiagen introduces EZ2 Connect platform
Qiagen has announced the upcoming launch of the EZ2 Connect product line, an automated sample-processing platform that aims to benefit biomedical research,...
Qiagen sales, earnings climb in Q3
Significant ongoing demand for COVID-19 testing and improved trends in other areas of Qiagen's product portfolio led to a 26% increase in preliminary...
Qiagen expands genomic tools for COVID-19 research
Qiagen launched a SARS-CoV-2 primer panel that converts viral RNA samples into libraries that are ready for next-generation sequencing of the novel coronavirus...
Thermo Fisher's acquisition of Qiagen falls short
Thermo Fisher Scientific has terminated its acquisition of Qiagen after the company was unable to secure the number of shares needed to proceed with the...

Copyright © 2021 scienceboard.net

Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter